

AMENDMENTS TO THE CLAIMS

Claims 1-49. (Canceled)

50. (Previously presented) A method of inhibiting proliferation of a liver epithelial tumor cell comprising the step of inhibiting FoxM1B activity in the liver epithelial tumor cell by contacting the cell with a p19ARF protein fragment, wherein the p19ARF protein fragment has the amino acid sequence as set forth in SEQ ID NO:10, and wherein the liver epithelial tumor cell expresses FoxM1B protein.
51. (Canceled)
52. (Canceled)
53. (Canceled)
54. (Previously Presented) A method of inhibiting proliferation of a liver tumor cell comprising the step of inhibiting FoxM1B activity in the liver tumor cell by contacting the cell with a p19ARF protein fragment, wherein the p19ARF protein fragment has the amino acid sequence as set forth in SEQ ID NO:10.
55. (Previously presented) The method of claim 54, wherein FoxM1B activity is inhibited by causing FoxM1B protein to localize in the nucleolus of the tumor cell.
56. (Previously Presented) The method of claim 54, wherein FoxM1B activity is inhibited by preventing FoxM1B nuclear localization.
57. (Previously presented) The method of claim 54, wherein the liver tumor cell is a malignant liver tumor cell.

58. (Previously presented) The method of claim 54, wherein the liver tumor cell is of epithelial cell origin.
59. (Previously presented) The method of claim 54, wherein the liver tumor cell is contacted with the p19ARF protein fragment *in vitro*.
60. (Previously presented) The method of claim 54, wherein the liver tumor cell is contacted with the p19ARF protein fragment *in vivo*.
61. (Previously presented) The method of claim 60, wherein an animal comprising the liver tumor cell is administered with a pharmaceutical composition comprising the p19ARF protein fragment.
62. (Previously presented) The method of claim 61, wherein the pharmaceutical composition further comprises at least one pharmaceutically acceptable carrier, diluent or excipient.
63. (Previously presented) The method of claim 61, wherein the pharmaceutical composition is administered to the animal parenterally.
64. (Previously presented) The method of claim 63, wherein the pharmaceutical composition is administered to the animal by intraperitoneal injection.
65. (Previously presented) The method of claim 61, wherein the animal is a human.
66. (Canceled)
67. (Canceled)
68. (Canceled)
69. (Canceled)

70. (Canceled)
71. (Canceled)
72. (Canceled)
73. (New) The method of claim 50 wherein the p19ARF protein fragment consists of the amino acid sequence as set forth in SEQ ID NO:10.
74. (New) The method of claim 54 wherein the p19ARF protein fragment consists of the amino acid sequence as set forth in SEQ ID NO:10.